PMID- 19495729
OWN - NLM
STAT- MEDLINE
DCOM- 20091116
LR  - 20211020
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 205
IP  - 3
DP  - 2009 Aug
TI  - Differential changes in mesolimbic dopamine following contingent and 
      non-contingent MDMA self-administration in mice.
PG  - 457-66
LID - 10.1007/s00213-009-1554-z [doi]
AB  - RATIONALE: There is evidence demonstrating changes in dopamine (DA) transmission 
      in the nucleus accumbens (NAc) related to contingent versus non-contingent drug 
      administration. OBJECTIVES: The aim of this study was to evaluate basal and 
      3,4-methylenedioxymethamphetamine (MDMA)-stimulated DA levels in the NAc of mice 
      that had previously received contingent and non-contingent infusions of MDMA. 
      Contingent mice were trained to self-administer MDMA (0.125 mg/kg/infusion) in 
      2-h sessions for 10 days. Yoked mice received either MDMA at the same dose or 
      saline. Forty-eight hours after the last MDMA or saline administration, DA levels 
      were measured by in vivo microdialysis before and after an MDMA (10 mg/kg, i.p.) 
      challenge. Binding of [(3)H]-mazindol and [(3)H]-citalopram was evaluated by 
      autoradiography. RESULTS: Animals receiving MDMA infusions showed significantly 
      lower basal DA levels than the yoked saline group. A reduced activation of DA was 
      observed following MDMA in contingent mice with respect to both yoked MDMA and 
      saline mice. No significant alterations in DA transporter or serotonin 
      transporter were observed in the three groups of mice. CONCLUSIONS: These results 
      suggest that prolonged exposure to MDMA in mice produces changes in basal DA 
      levels after drug withdrawal and a decreased neurochemical response at the level 
      of the mesolimbic DA reward pathway that is, in part, related to instrumental 
      learning during self-administration.
FAU - Orejarena, Maria Juliana
AU  - Orejarena MJ
AD  - Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, PRBB, Calle Dr. 
      Aiguader, 88, 08003 Barcelona, Spain.
FAU - Berrendero, Fernando
AU  - Berrendero F
FAU - Maldonado, Rafael
AU  - Maldonado R
FAU - Robledo, Patricia
AU  - Robledo P
LA  - eng
GR  - 5 R01DA016768/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20090604
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Hallucinogens)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Amphetamine-Related Disorders/metabolism/psychology
MH  - Animals
MH  - Dopamine/*metabolism
MH  - Dopamine Plasma Membrane Transport Proteins/physiology
MH  - Dose-Response Relationship, Drug
MH  - Extinction, Psychological
MH  - Hallucinogens/*administration & dosage/pharmacology
MH  - Injections, Intravenous
MH  - Limbic System/*drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Microdialysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage/pharmacology
MH  - Nucleus Accumbens/drug effects/metabolism
MH  - Self Administration
MH  - Serotonin Plasma Membrane Transport Proteins/physiology
MH  - Substance Withdrawal Syndrome/metabolism/psychology
EDAT- 2009/06/06 09:00
MHDA- 2009/11/17 06:00
CRDT- 2009/06/05 09:00
PHST- 2008/10/07 00:00 [received]
PHST- 2009/04/22 00:00 [accepted]
PHST- 2009/06/05 09:00 [entrez]
PHST- 2009/06/06 09:00 [pubmed]
PHST- 2009/11/17 06:00 [medline]
AID - 10.1007/s00213-009-1554-z [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2009 Aug;205(3):457-66. doi: 
      10.1007/s00213-009-1554-z. Epub 2009 Jun 4.